Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Short-term Investments (2020 - 2023)

Historic Short-term Investments for Ascendis Pharma A (ASND) over the last 4 years, with Q4 2023 value amounting to $7.8 million.

  • Ascendis Pharma A's Short-term Investments fell 5475.54% to $7.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $7.8 million, marking a year-over-year decrease of 5475.54%. This contributed to the annual value of $7.8 million for FY2023, which is 5475.54% down from last year.
  • Per Ascendis Pharma A's latest filing, its Short-term Investments stood at $7.8 million for Q4 2023, which was down 5475.54% from $17.3 million recorded in Q4 2022.
  • Over the past 5 years, Ascendis Pharma A's Short-term Investments peaked at $350.5 million during Q1 2020, and registered a low of $1.3 million during Q1 2022.
  • For the 4-year period, Ascendis Pharma A's Short-term Investments averaged around $46.2 million, with its median value being $5.2 million (2021).
  • Its Short-term Investments has fluctuated over the past 5 years, first plummeted by 9721.01% in 2021, then surged by 23376.85% in 2022.
  • Ascendis Pharma A's Short-term Investments (Quarter) stood at $3.2 million in 2020, then skyrocketed by 64.36% to $5.2 million in 2021, then skyrocketed by 233.77% to $17.3 million in 2022, then crashed by 54.76% to $7.8 million in 2023.
  • Its last three reported values are $7.8 million in Q4 2023, $17.3 million for Q4 2022, and $4.3 million during Q3 2022.